University of Notre Dame DU Lac Raises Position in Nektar Therapeutics (NKTR)

University of Notre Dame DU Lac increased its position in shares of Nektar Therapeutics (NASDAQ:NKTR) by 5.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 131,757 shares of the biopharmaceutical company’s stock after purchasing an additional 7,125 shares during the quarter. University of Notre Dame DU Lac owned approximately 0.08% of Nektar Therapeutics worth $3,162,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. BlackRock Inc. increased its position in shares of Nektar Therapeutics by 0.9% during the second quarter. BlackRock Inc. now owns 20,221,479 shares of the biopharmaceutical company’s stock worth $395,330,000 after purchasing an additional 185,933 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Nektar Therapeutics by 3.0% during the second quarter. Vanguard Group Inc. now owns 14,009,894 shares of the biopharmaceutical company’s stock worth $273,893,000 after purchasing an additional 401,914 shares in the last quarter. State Street Corp increased its position in shares of Nektar Therapeutics by 11.3% during the second quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock worth $86,179,000 after purchasing an additional 447,023 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Nektar Therapeutics by 0.6% during the second quarter. Bank of New York Mellon Corp now owns 2,138,632 shares of the biopharmaceutical company’s stock worth $41,812,000 after purchasing an additional 12,730 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Nektar Therapeutics by 7.2% during the second quarter. Northern Trust Corp now owns 1,937,352 shares of the biopharmaceutical company’s stock worth $37,877,000 after purchasing an additional 130,294 shares in the last quarter. Hedge funds and other institutional investors own 96.04% of the company’s stock.

In other news, CEO Howard W. Robin sold 83,333 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $21.54, for a total value of $1,794,992.82. Following the transaction, the chief executive officer now owns 235,837 shares of the company’s stock, valued at approximately $5,079,928.98. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christopher A. Kuebler sold 4,000 shares of the company’s stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $21.86, for a total value of $87,440.00. Following the completion of the transaction, the director now directly owns 40,500 shares in the company, valued at approximately $885,330. The disclosure for this sale can be found here. In the last ninety days, insiders sold 941,427 shares of company stock worth $24,663,626. Corporate insiders own 5.44% of the company’s stock.

NKTR has been the subject of several research reports. BidaskClub upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. HC Wainwright started coverage on Nektar Therapeutics in a research report on Monday, August 7th. They set a “buy” rating and a $31.00 price target for the company. Mizuho boosted their price objective on Nektar Therapeutics from $30.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, November 14th. Jefferies Group reissued a “buy” rating and set a $35.00 price objective on shares of Nektar Therapeutics in a research note on Wednesday, November 8th. Finally, Canaccord Genuity boosted their price objective on Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $35.58.

Nektar Therapeutics (NASDAQ:NKTR) opened at $50.73 on Tuesday. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $55.42.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.16. The company had revenue of $152.90 million for the quarter, compared to analyst estimates of $126.50 million. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The firm’s revenue for the quarter was up 321.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.32) earnings per share. sell-side analysts predict that Nektar Therapeutics will post -0.75 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.chaffeybreeze.com/2017/12/05/university-of-notre-dame-du-lac-raises-position-in-nektar-therapeutics-nktr.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply